Difference between revisions of "Ruxolitinib (Jakafi)"
m |
|||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
None available at this time. | None available at this time. | ||
| − | |||
| − | |||
| − | |||
| − | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 05:04, 11 January 2012
Also formerly known as INCB018424.
General information
Class/mechanism: kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
None available at this time.